Belgium: Agomab to acquire Origo Biopharma

Agomab Therapeutics, which develops treatments that aim to resolve fibrosis, repair tissue structure and restore organ function, has entered into a definitive agreement under which it will acquire Origo Biopharma, a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders….

You must be a HMI Subscriber to view this content.

Subscribe Now »